Logo of Proteomics International Laboratories (ASX:PIQ)Latest Proteomics International Laboratories (ASX:PIQ) News

Page 2
Page 2 of 5

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

Proteomics International Secures Exclusive National Distribution with Healius for Promarker Tests

Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.
Ada Torres
22 July 2026

Healthcare Wrap - Week 28 (6 July -> 10 July) 2026

Healthcare stocks swung hard this week as debt clean-ups, fresh funding and product sales updates drove the biggest moves. The strongest gains came from companies with clear near-term cash or commercial news, while some early spikes faded once trading settled.
Logan Eniac
11 July 2026

Proteomics International Secures US Patent for PromarkerEndo Endometriosis Test

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.
Ada Torres
8 July 2026

Healthcare Wrap - Week 19 (4 May -> 8 May) 2026

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.
Logan Eniac
9 May 2026

Proteomics International Denies Undisclosed Info Amid Strategic Overhaul and Share Volatility

Proteomics International Laboratories (ASX:PIQ) has denied any undisclosed material information following a sharp share price drop and heightened trading activity, pointing instead to recent strategic updates and organisational changes.
Ada Torres
7 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Proteomics International Advances Commercial Launch of Diagnostic Tests with Distributor Model

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.
Ada Torres
28 Apr 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.
Logan Eniac
18 Apr 2026

Proteomics International Cuts 25% Staff, Appoints CFO, Signals Commercial Shift

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.
Ada Torres
17 Apr 2026

Proteomics International Secures Canadian Patent for Breakthrough Esophageal Cancer Test

Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.
Ada Torres
16 Jan 2026

Proteomics International Taps David Morris to Accelerate Promarker® Growth

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.
Ada Torres
14 Jan 2026